Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%

Healthcare

Page 67
  1. Feb 02, 2026 · 12:20 · DR

    Medical Facilities completes sale of interest in OSH

    Medical Facilities completes sale of interest in OSH

    01
  2. Feb 02, 2026 · 12:10 · SHRX

    Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes

    Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes

    02
  3. Feb 02, 2026 · 09:28 · PHRM

    PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

    PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

    03
  4. Feb 02, 2026 · 09:01 · TTI

    Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

    Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

    04
  5. Feb 02, 2026 · 08:00 · NURS

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    05
  6. Feb 02, 2026 · 08:00 · VST

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    06
  7. Feb 02, 2026 · 07:03 · TLT

    Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

    Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

    07
  8. Feb 02, 2026 · 07:00 · NLH

    Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

    Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

    08
  9. Feb 02, 2026 · 07:00 · DR

    Medical Facilities Corporation Announces Sale of Oklahoma Spine Hospital, LLC and The Surgery Center of Newport Coast, LLC

    Medical Facilities Corporation Announces Sale of Oklahoma Spine Hospital, LLC and The Surgery Center of Newport Coast, LLC

    09
  10. Feb 02, 2026 · 03:06 · SEGN

    Seegnal prescription platform used by Israeli hospital

    Seegnal prescription platform used by Israeli hospital

    10
  11. Jan 30, 2026 · 18:55 · OTC

    Ocumetics seeks TSX-V OK for forbearance agreement

    Ocumetics seeks TSX-V OK for forbearance agreement

    11
  12. Jan 30, 2026 · 16:26 · METX

    ME Therapeutics talks pipeline and in vivo CAR plans

    ME Therapeutics talks pipeline and in vivo CAR plans

    12
  13. Jan 30, 2026 · 08:00 · 4151

    Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

    Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

    13
  14. Jan 29, 2026 · 18:00 · 4875

    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

    14
← Newer Older →